Research programme: neurological disease therapeutics - Servier/Crossbeta Biosciences
Latest Information Update: 30 Oct 2015
At a glance
- Originator Crossbeta Biosciences; Servier
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 05 Oct 2015 Early research in Neurological disorders in Netherlands (unspecified route)
- 05 Oct 2015 Early research in Neurological disorders in France (unspecified route)